Find disease awareness content and relevant supporting materials
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy
The past two decades have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL), particularly with the introduction of targeted therapies to clinical practice.
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease
Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...
Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice
Objectives: This study was conducted to investigate the real-world effectiveness and tolerability of rituximab-containing chemoimmunotherapies, which have become the standard of care for chronic lymphocytic leukaemia (CLL), particularly for physically fit patients.
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi?centre retrospective analysis of 105 R/R CLL patients who received venetoclax...
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. In CML, the acquisition of the fusion...